MORRIS PLAINS, N.J., May 31, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 9 presentations, of which 7 are oral presentations, will be given at the 58th Annual Meeting of the Society of Nuclear Medicine (SNM), scheduled for June 4 – 8, 2011, in San Antonio, TX.
Four of the oral presentations will be to provide updates on clinical trials involving the Company's proprietary monoclonal antibodies, highlighted by the Phase Ib/II study with yttrium-90-labeled (90Y) clivatuzumab in combination with gemcitabine as a frontline therapy in patients with previously untreated advanced pancreatic cancer. First results from an investigator-sponsored study of TF2, a bispecific antibody constructed using the patented Dock-and-Lock technology that targets the carcinoembryonic antigen (CEA), for pretargeted radiation therapy of patients with colorectal cancer will also be presented.
The French study group, GOELAMS, will report interim efficacy results from their multicenter, Phase II study of 90Y-epratuzumab as a consolidation therapy in aggressive non-Hodgkin's lymphoma. The final clinical study to be updated at this year's SNM meeting will be on pretargeted radioimmunotherapy in progressive medullary thyroid cancer using a bispecific antibody derived from labetuzumab, the Company's humanized anti-CEA antibody.
The schedule and meeting places for the oral presentations and scientific poster sessions, together with the publication numbers, are listed below:
- "Pretargeted radioimmunotherapy (pRAIT) in progressive medullary thyroid cancer (MTC)" [Publication No. 125, Scientific Paper Session (Oral), Session Info: Endocrinology: Neuroendocrine Tumors (Integrated Session), Monday, June 6, 10:36 a.m. – 10:48 a.m., Room 214A]
- "Targeting GRPR-expressing tumors with an 18F-labeled bombesin analog" [Publication No. 297, Scientific Paper Session (Oral), Session Info: Novel Radioactive Probes II: Tumor Probes – Part 1, Tuesday, June 7, 9:00 a.m. – 9:12 a.m., Room 214BC]
- "Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y-epratuzumab tetraxetan following R-CHOP in elderly diffuse large B-cell lymphoma (DLBCL) patients" [Publication No. 355, Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy II: Radioimmunotherapy, Tuesday, June 7, 9:45 a.m. – 9:57 a.m., Room 217B]
- "Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC)" [Publication No. 357, Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy II: Radioimmunotherapy, Tuesday, June 7, 10:09 a.m. – 10:21 a.m., Room 217B]
- "Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): First results" [Publication No. 358, Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy II: Radioimmunotherapy, Tuesday, June 7, 10:21 a.m. – 10:33 a.m., Room 217B]
- "A rapid method for F-18 labeling of proteins for PET" [Publication No. 572, Scientific Paper Session (Oral), Session Info: Novel Radioactive Probes III: Labeling Methods and Others, Wednesday June 8, 9:45 a.m. – 9:57 a.m., Room 214BC]
- "Evaluation of 1,4,7-triazacyclononane-1,4-diacetate (NODA) ligand for the development of PET imaging agents" [Publication No. 577, Scientific Paper Session (Oral), Session Info: Novel Radioactive Probes III: Labeling Methods and Others, Wednesday June 8, 10:45 a.m. – 10:57 a.m., Room 214BC]
- "A facile kit for F-18 radiolabeling of peptides for PET" [Publication No. 1489, Scientific Poster Session, Poster Section: Novel Radioactive Probes Posters, Monday June 6, 2:30 p.m. – 4:00 p.m., Exhibit Hall B]
- "Pretargeting of prostate cancer with an internalizing anti-EGP-1 x anti-HSG bispecific antibody" [Publication No. 1680, Scientific Poster Session, Poster Section: Basic Science Posters (Oncology), Tuesday, June 7, 2:30 p.m. – 4:00 p.m., Exhibit Hall B]
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 178 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at . The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties, and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products, and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. Chau Cheng Director, Investor Relations & Grant Management (973) 605-8200, extension 123 ccheng@immunomedics.com
